glioblastoma

[Cell Death & Disease] Scientists evaluated the functional activity and mechanism of TAK-243 in preclinical models of glioblastoma multiforme.

[Oblato, Inc.] Oblato, Inc. announced that it has received an agreement from the FDA for its plan to submit an intermediate size expanded access protocol for use of OKN-007 in patients with high-grade gliomas.

[Cell Death & Disease] Researchers mapped the manifold effects of glutamate signaling in glioblastoma (GBM) as the basis to further discover the regulatory role and interactions of specific receptors, within the GBM microenvironment.

[Omniscient Neurotechnology, Inc. (BusinessWire, Inc.)] Omniscient Neurotechnology, Inc. announced that it has received US FDA 510(k) clearance for Quicktome™, a digital brain mapping platform that allows neurosurgeons to visualize and understand a patient's brain networks prior to performing life-changing brain surgery.

[Scientific Reports] The authors demonstrated that FOSL1 directly regulated four transcription factors bond to their promoter regions, was involved in the deregulation of several stemness markers, and reduced the cells’ ability to generate aggregates increasing the extracellular matrix component FN1.

[Scientific Reports] Scientists demonstrated that tunneling nanotubes structures were induced between glioblastoma cells and surrounding non-tumor astrocytes to transfer tumor-derived mitochondria.